This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Today's Health Winners and Losers

Shares of Beckman Coulter (BEC) were among the health-related losers Friday, falling 5% after the maker of biomedical testing instruments posted mixed fourth-quarter results and issued lower-than-expected first-quarter guidance.

In the fourth quarter, the company earned $17.8 million, or 28 cents a share, on sales of $655.5 million. Excluding items, the company earned $46.9 million, or 73 cents a share. Analysts polled by Thomson First Call expected a lower profit of 72 cents a share, but higher sales of $668.6 million. During the year-earlier period, the company earned $59.8 million, or 91 cents a share, on sales of $693 million.

Looking ahead, Beckman Coulter sees first-quarter earnings of 30 cents to 40 cents a share, including stock-based compensation costs of 5 cents a share. Analysts project earnings, excluding stock-based compensation costs, of 64 cents a share. The company predicts sales of $555 million to $575 million, below analysts' target of $582.1 million. For 2006, Beckman Coulter continues to see earnings of $2.70 to $2.90 a share, including stock-based compensation costs of about 20 cents a share, on sales of $2.53 billion to $2.6 billion. Analysts project earnings, excluding stock-based compensation costs, of $3.02 a share on sales of $2.56 billion. Shares were trading down $3.25 to $56.91.

American Pharmaceutical Partners (APPX) rose 3% after the drugmaker posted fourth-quarter earnings that topped forecasts. The company earned $23.4 million, or 32 cents a share, on sales of $144.8 million. Excluding items, the company earned $28.2 million, or 38 cents a share. Analysts expected earnings of 35 cents a share, before items. A year earlier, the company earned $21.9 million, or 30 cents a share, on sales of $122.6 million. Shares were trading up $1.02 to $32.63.

Shares of NuVasive (NUVA - Get Report) fell 2.5% after a lower-than-expected sales guidance overshadowed fourth-quarter results that topped expectations. The medical device company posted a fourth-quarter loss of $4.2 million, or 17 cents a share, on sales of $18.6 million. Excluding items, the company reported a loss of $3.4 million, or 14 cents a share. Analysts expected a loss of 15 cents a share, before items, on sales of $18.3 million. During the year-earlier quarter, the company recorded an adjusted loss of $1.9 million, or 8 cents a share, on sales of $11.8 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
ELN $0.00 0.00%
AMGN $167.23 2.20%
NPSP $45.97 0.02%
NUVA $43.40 4.45%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs